BioXcel Therapeutics, Inc.

BTAINasdaqCM

$0.07▲ +0.07 (+0.00%)

Market closedData as of 03:07 PM ET · 15-min delay

Analyst ratingnone

Every calculator, already run for BTAI

What is it worth?

P/E calculatorHow does this multiple compare to peers and its own history?Run →DCF calculatorTen years of free cash flow, discounted back to today.Run →Reverse DCFSolves the price backwards for the growth it already requires.Run →EV / EBITDAThe price with debt added and cash netted off.-2.1x PEG ratioThe multiple divided by the growth meant to justify it.Run →Graham numberGraham's ceiling from earnings and book value.Run →P/S ratioFor companies whose earnings are not the point yet.3.1x Intrinsic valueDCF, multiples and Graham run together as one range.Run →

Is it any good?

ROIC calculatorWhether a dollar invested earns more than it costs.Run →Altman Z-scoreFive balance-sheet ratios weighted into a distress score.-26.56 · distress Piotroski F-scoreNine pass-fail tests on profit, leverage and efficiency.3 of 9 Debt to equityHow much of the balance sheet is borrowed.-1.09 Interest coverageHow many times operating profit covers the interest bill.3x Profit marginGross, operating and net, each against the sector.0.0% net Free cash flowOperating cash after the capex needed to keep going.-$32M Rule of 40Revenue growth plus margin, the software health line.

What does it return & pay?

ROE calculatorProfit against the equity shareholders left in.Run →EPS growthEarnings per share compounded over the filings.Run →CAGR calculatorCompound rate on revenue, earnings, cash or price.20% rev Dividend yieldWhat it pays, and whether free cash flow covers it.0.00%Net payout yieldDividends plus buybacks, less shares issued.Run →Owner earningsBuffett's version: cash a buyer could actually take out.-$32M

You have the numbers on BTAI. Get the argument.

A written report on which of these readings actually decide the outcome for BioXcel Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.

Key market data

Market cap$2.31M

P/E (TTM)—

Forward P/E-0.0x

Beta0.19

EPS (TTM)$-2.58

Dividend yield—

Volume47.48M

Avg volume6.31M

52-week range

$0.02$2.96

Analyst consensus

1 analysts covering BTAI

Buy1

Hold0

Sell0

Ownership & short interest

Institutions26.0%

Insiders3.6%

Shares out$31.31M

Insider Trading Activity for BTAI

Insider	Role	Type	Shares	Price	Value	Date	Filing

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid…

29 employeesUnited States

BTAI — frequently asked

Is BTAI a buy right now?

Wall Street's consensus rating on BioXcel Therapeutics, Inc. is none across 1 analysts. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.

Compare BioXcel Therapeutics, Inc. against related stocks

Explore additional stock overview pages and jump directly into full report generation for each symbol.

Nearby tickers

Additional public equities from our tracked universe.

BSVN stock overview BRT stock overview BWA stock overview BRK-B stock overview BWFG stock overview BRBR stock overview BX stock overview

Market leaders

Large-cap symbols investors frequently compare.

AAPL stock overview MSFT stock overview NVDA stock overview AMZN stock overview GOOGL stock overview META stock overview TSLA stock overview JPM stock overview

Investor Guides For BioXcel Therapeutics, Inc.

Start with the evergreen guides that matter most for this sector, then move back into the ticker page when you want to pressure-test the framework on a live name.

Investor FoundationsStock valuation: frame the implied case before the model Investor FoundationsDCF: model the economics before the spreadsheet does Investor FoundationsDCF sensitivity: make the fragile assumptions visible Investor FoundationsStock multiples: read the argument inside the number

Generate your full BTAI research report

DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on BioXcel Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.